Squamous Cell Carcinoma Clinical Trial
Official title:
Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients
The purpose of this study is to study the effect of 13-cis retinoic acid in preventing second primary malignancy in the oral cavity cancer patients after curative local treatment and to study the toxicity and compliance of 13-cis retinoic acid.
There are more than one thousand deaths annually from head and neck cancer in Taiwan
(excluding nasopharyngeal carcinoma) and the majority of treatment failures are related to
recurrence of primary disease. Only patients with early-stage disease have high cure rates,
but they remain at risk for the development of second primary tumors.
Second primary malignancies occur at a constant annual rate of 5% to 7% in all head and neck
cancer patients1. Furthermore, because the mortality from primary disease recurrence
plateaus after 2 to 3 years in patients with locally advanced disease, second primary tumors
become the major cause of late cancer mortality.
Sporn et al defined chemoprevention as an effort to arrest or reverse premalignant cells
during their progression to invasive malignancy2,3. The concept of chemoprevention has
evolved to include the use of specific compounds, rather than general dietary changes, to
prevent the development of cancer.
Hong et al studied the effects of 13-cis retinoic acid on patients with history of head and
neck cancers 4. After treatment of head and neck primary cancers with either radiotherapy or
surgery or both, 103 patients were randomized to receive either adjuvant 13-cis retinoic
acid or placebo. In an update of this trial with 55 months of follow-up, 16 patients (31%)
in the placebo group had developed second primary tumors, whereas 7 patients (14%) in the
treatment group had developed second primary tumors (p=0.04) 5. Betel quid chewing becomes
increasingly popular in Taiwan. Exposure to both smoking and betel quid significantly
increases the risk of oral cavity cancer6. The hazard of developing second primary tumors is
high in this population, therefore, chemoprevention is worthy of trial.
Use of 13-cis RA for chemoprevention of head and neck cancer only has been published by Hong
et al. Their cases included a variety of head and neck cancers that are known to be not a
homogenous group. The risk of second primary is different for different primary sites.
Therefore, the value of 13-cis RA in chemoprevention is not conclusively addressed. In our
proposal, only oral cavity cancer is included and the result will be more convincing. The
result could be the basis of further chemoprevention clinical trial or guideline for
clinical practice.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02213133 -
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
|
Phase 2 | |
Not yet recruiting |
NCT04533321 -
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Active, not recruiting |
NCT01232374 -
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01208883 -
A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer
|
Phase 1 | |
Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
Completed |
NCT01089803 -
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
|
N/A | |
Terminated |
NCT00707655 -
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
|
Phase 1/Phase 2 | |
Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
Completed |
NCT01127737 -
Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
|
N/A | |
Completed |
NCT00409565 -
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00176267 -
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
|
Phase 2 | |
Terminated |
NCT04685798 -
Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT
|
N/A | |
Recruiting |
NCT04370587 -
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Not yet recruiting |
NCT05852665 -
Buccal Cancer Resection Ultrasound Guided
|
N/A | |
Recruiting |
NCT05048459 -
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
|
N/A | |
Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 |